8-K Announcements
6Material company update
May 27, 2026·SEC
Material company update
May 20, 2026·SEC
Material company update
Mar 4, 2026·SEC
Liminatus Pharma, Inc. Class A Common Stock(LIMN)Earnings, Financials & Key Ratios
LIMN•NASDAQ
$0.11
Price updated Jun 27, 2026
AboutLiminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.Show more
- Revenue$0
- EBITDA-$3M-8.0%
- Net Income-$10M-251.4%
- EPS (Diluted)-0.43-7.5%
LIMN Price & Volume
Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock price & volume — 10-year historical chart
Loading chart...
Liminatus Pharma Faces Imminent Clinical Liquidity Crisis
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
"Liminatus Pharma remains a pre-commercial entity with zero revenue generation, leaving the firm entirely dependent on external capital to fund its ongoing research and development. The company's financial position is characterized by persistent operating losses, including a $1.1M loss in 2026Q1, and a severely constrained balance sheet that suggests a high probability of near-term dilution or insolvency. Investors should exercise extreme caution as the current cash balance of $337,655 is insufficient to cover the quarterly operating burn rate."
Verdict Logic
Negative: The company's current ratio of 0.05 and a $1.1M quarterly operating loss indicate an imminent liquidity crisis that threatens the viability of the equity.
LIMN Growth Metrics
Liminatus Pharma, Inc. Class A Common Stock (LIMN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-437.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM85.54%
Return on Capital
10 Years-16.28%
5 Years-16.28%
3 Years-46.02%
Last Year-
LIMN Recent Earnings
Liminatus Pharma, Inc. Class A Common Stock (LIMN) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.03
—
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.03
—
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.07
—
Rev
—
—
Q4 2025
Oct 3, 2025Metric
Actual
Est
EPS
$0.05
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.03 | — |
| Q2 2026 | Mar 31, 2026 | $0.03 | — |
| Q4 2025 | Nov 13, 2025 | $0.07 | — |
| Q4 2025 | Oct 3, 2025 | $0.05 | — |
Based on last 4 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Liminatus Pharma, Inc. Class A Common Stock (LIMN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.11 | $2.84M | -0.25 | — | — | — | — | |
| $3.92 | $281.16M | 11.88 | -31.8% | 21.61% | 10.62% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — |
Compare LIMN vs Peers
Liminatus Pharma, Inc. Class A Common Stock (LIMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LIMN SEC Filings & Documents
Liminatus Pharma, Inc. Class A Common Stock (LIMN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when LIMN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LIMN Frequently Asked Questions
Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is LIMN profitable?
Liminatus Pharma, Inc. Class A Common Stock (LIMN) reported a net loss of $11.0M for fiscal year 2025.
Dividend & Returns
What is Liminatus Pharma, Inc. Class A Common Stock's free cash flow?
Liminatus Pharma, Inc. Class A Common Stock (LIMN) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.